Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.48 |
| ▸ | MMP3 | P08254 | 9/20 | 0.48 |
| ▸ | MMP1 | P03956 | 6/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14233744 | 0.83 | TUBB1 (0.42) | MMP2MMP3MMP1ADAM17TNF | |
| SCHEMBL22111365 | 0.83 | ALDH1A1 (0.43) | — | |
| SCHEMBL16644131 | 0.79 | TUBB1 (0.49) | MMP2MMP3MMP1ADAM17 | |
| SCHEMBL22661839 | 0.77 | CNR2 (0.39) | MMP2MMP3MMP1ADAM17TNF | |
| SCHEMBL19522596 | 0.76 | TUBB1 (0.41) | MMP2MMP3MMP1ADAM17TNF | |
| SCHEMBL20015459 | 0.76 | TUBB1 (0.41) | MMP2MMP3MMP1ADAM17TNF | |
| SCHEMBL6674366 | 0.76 | TUBB1 (0.64) | MMP2MMP3MMP1ADAM17TNF | |
| SCHEMBL16730694 | 0.76 | TUBB1 (0.41) | MMP2MMP3MMP1ADAM17TNF | |
| SCHEMBL14233968 | 0.76 | TUBB1 (0.64) | MMP2MMP3MMP1ADAM17TNF | |
| SCHEMBL88817 | 0.75 | TUBB1 (0.51) | MMP2MMP3MMP1ADAM17TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | SORRENTO THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | ERBB2, ABCG2, DYNLL2 | MMP2 3070/4885MMP3 3186/4885MMP1 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.